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Visceral leishmaniasis (VL) is a zoonotic disease that is endemic to Brazil, where dogs are the main domestic parasite reservoirs,
and the percentages of infected dogs living in regions where canine VL (CVL) is endemic have ranged from 10% to 62%. Despite
technological advances, some problems have been reported with CVL serodiagnosis. The present study describes a sequential
subtractive selection through phage display technology from polyclonal antibodies of negative and positive sera that resulted in
the identification of potential bacteriophage-fused peptides that were highly sensitive and specific to antibodies of CVL. A nega-
tive selection was performed in which phage clones were adhered to purified IgGs from healthy and Trypanosoma cruzi-infected
dogs to eliminate cross-reactive phages. The remaining supernatant nonadhered phages were submitted to positive selection
against IgG from the blood serum of dogs that were infected with Leishmania infantum. Phage clones that adhered to purified
IgGs from the CVL-infected serum samples were selected. Eighteen clones were identified and their reactivities tested by a phage
enzyme-linked immunosorbent assay (phage-ELISA) against the serum samples from infected dogs (n 31) compared to those
from vaccinated dogs (n 21), experimentally infected dogs with cross-reactive parasites (n 23), and healthy controls (n
17). Eight clones presented sensitivity, specificity, and positive and negative predictive values of 100%, and they showed no cross-
reactivity with T. cruzi- or Ehrlichia canis-infected dogs or with dogs vaccinated with two different commercial CVL vaccines in
Brazil. Our study identified eight mimotopes of L. infantum antigens with 100% accuracy for CVL serodiagnosis. The use of
these mimotopes by phage-ELISA proved to be an excellent assay that was reproducible, simple, fast, and inexpensive, and it can
be applied in CVL-monitoring programs.
Leishmaniasis consists of a wide range of diseases found in 98countries and three territories, with approximately 1.6 million
cases occurring each year and with an incidence of 40,000 deaths
registered per year (1). Canine visceral leishmaniasis (CVL)
caused by Leishmania infantum is a major global zoonosis that is
potentially fatal to humans and dogs; it can be found in the regions
of southern Europe, Africa, Asia, and Central and South America,
and it is considered endemic to approximately 70 countriesworld-
wide (2, 3). However, CVL is expanding in its geographic distri-
bution throughout the Western Hemisphere, where it now is
found from northern Argentina to the United States (4), even
reaching as far as the provinces of southern Canada (5). CVL is
also an important concern in countries that are not endemic for
the disease, as imported sick or infected dogs constitute a veteri-
nary and public health problem (6). Brazilian public health au-
thorities currently use the enzyme-linked immunosorbent assay
(ELISA) as a screening test and the indirect immunofluorescence
antibody test (IFAT), with a cutoff titer of 1:40, as a confirmatory
analysis to determine the clinical status of dogs (7). Moreover,
controlling the spread of CVL in Brazil is mainly based on the
elimination of seropositive dogs (8).
The serodiagnosis of CVL, however, is hampered by various
factors, mainly due to the variable sensitivity and/or specificity
values obtained with the different antigens employed, leading to
the occurrence of a large number of false-positive results caused
by cross-reactivity with other organisms, such as Trypanosoma
cruzi and Trypanosoma caninum (9–12), Leishmania braziliensis
(9, 13), and Ehrlichia canis (14, 15). Additionally, there are two
commercially available Brazilian vaccines used to prevent CVL
that can induce the production of high levels of Leishmania-spe-
cific antibodies in vaccinated animals, causing them to be diag-
nosed as infected animals in distinct serological trials (16).
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Phage display is a technology based on DNA recombination,
resulting in the expression of foreign peptide variants on the outer
surface of phage clones. Using a refined in vitro selection process
based on binding affinity and so-called biopanning cycles, pep-
tides exposed in the selected phage clones are analyzed by DNA
sequencing and then identified (17–19). One of the earliest appli-
cations of phage display was the study of antigen-antibody bind-
ing aimed at identifying mimotopes (peptides that mimic linear,
discontinuous, and even nonpeptide epitopes [20]), which were
recognized by specific monoclonal or polyclonal antibodies ap-
plied in the diagnoses and/or vaccines against some diseases, such
as malaria (21–23), toxoplasmosis (24, 25), and Chagas’ disease
(26).
In the present study, a subtractive phage display selection was
employed to identify mimotopes that may be promptly used in
CVL serodiagnosis. These selected phage clones were serologically
relevant in a panel of several controls using a direct phage-ELISA.
Therefore, this work analyzes this significant improvement in
CVL serodiagnosis with high sensitivity and specificity, and it has
implications in animal control programs in regions that are en-
demic for the disease.
MATERIALS AND METHODS
Ethics statement. The experiments in this study were performed in com-
pliance with the Committee on the Ethical Handling of Research Animals
of the Federal University of Minas Gerais (UFMG), which approved this
study under protocol no. 043/2011.
Study animals. The sample size of this study consisted of 77 domestic
dogs (Canis lupus familiaris) made up of males and females of different
breeds and ages, collected from an area of Belo Horizonte, Minas Gerais,
Brazil, that is endemic for CVL. The blood serum samples from animals
with CVL were selected on the basis of two serological tests (IFAT [IFAT-
LVC Bio-Manguinhos kit] and ELISA [EIE-LVC Bio-Manguinhos kit],
both from Bio-Manguinhos, Fiocruz, Brazil) for Leishmania spp. Dogs
with an IFAT titer of 1:40 or ELISA reactivity below the cutoff value
indicated by the manufacturer were considered to be seronegative. Ani-
mals with an IFAT titer of1:40 and an ELISA value over the cutoff were
considered to be seropositive. Thus, symptomatic dogs (n  16) were
those that were positive by IFAT and ELISA but that also had positive
parasitological results by restriction fragment length polymorphism PCR
(PCR-RFLP) in blood samples, and which presented more than three
clinical symptoms (weight loss, alopecia, adenopathy, onychogryphosis,
hepatomegaly, conjunctivitis, and exfoliative dermatitis on the nose, tail,
and ear tips). Asymptomatic dogs (n  15) also presented positive sero-
logical (IFAT and ELISA) and parasitological (PCR-RFLP in blood sam-
ples) results, but they did not present any clinical signals or symptoms of
leishmaniasis. Healthy dogs (n  17) were selected from an area of Belo
Horizonte that is endemic for CVL, and they presented negative serolog-
ical (IFAT and ELISA) and parasitological (PCR) results and they were
free of any clinical signs or symptoms of leishmaniasis. Healthy animals
vaccinated with Leish-Tec (n 15) or Leishmune (n 6) were isolated in
kennels to prevent their contact with transmitting vectors of leishmaniasis
andwith dogs that had been experimentally infectedwithT. cruzi (n 15)
or E. canis (n 8), which also were used in this study. These blood serum
samples were obtained from previous projects that evaluated the immune
responses in these infected animals (27, 28). The serum samples were
provided by Alexandre Barbosa Reis (Departamento de Análises Clínicas,
Federal University of Ouro Preto, Ouro Preto, Brazil), Maria Norma
Mello (Departamento de Parasitologia, Universidade Federal de Minas
Gerais, BeloHorizonte, Brazil), and Ana Paula Fernandes (Departamento
de Análises Clínicas e Toxicológicas, Universidade Federal de Minas
Gerais, Belo Horizonte, Brazil).
Purification of antibodies by coupling in protein G microspheres.
The purification of IgG antibodies from the serum samples of the different
groups was performed by coupling to magnetic microspheres (magnetic
beads) conjugated to protein G (Dynabeads; Invitrogen). To this end, 2
109 particles of microspheres were washed 3 times in 1 ml of 0.1 M 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (pH 5.0), and the follow-
ing were added: 375l of pooled blood serum samples from healthy dogs,
150 l of pooled serum samples from T. cruzi-infected dogs, 300 l of
pooled serum samples from dogs with symptomatic VL or 195 l of
pooled serum samples from dogs with asymptomatic VL. An incubation
of 40min was performedwith constant stirring at room temperature. The
microspheres coupled with the antibodies were washed 3 times using 1ml
of 0.1MMES buffer in order to remove the nonadhered antibodies. Next,
the bead-antibody system was washed twice with 1 ml of 0.2M triethano-
lamine buffer (pH 8.2) and resuspended in 1 ml of covalent coupling
buffer (containing 20 mM dimethyl pimelimidate-HCl diluted in trieth-
anolamine buffer) for 30min, with constant stirring and at room temper-
ature. The neutralization of unbound reactive sites was made by incubat-
ing 1 ml of 50 mM Tris-base (pH 7.5) for 15 min at room temperature.
The microspheres were washed 3 times with 1 ml of TBS-T (50 mM Tris-
HCl [pH 7.5], 150 mM NaCl, and 0.1% of Tween 20), blocked by the
addition of 2 ml of blocking solution (5% bovine serum albumin [BSA]
diluted in TBS-T) for 1 h at 37°C and then resuspended in 200 l of TBS
buffer. To verify the coupling, 5l of beads coupled using IgGs was incu-
bated for 1 h at 37°C with an anti-dog IgG peroxidase antibody (1:5,000
dilution), and then they were washed 3 times with 1 ml of TBS-T, and the
reaction was developed by adding 3,3=,5,5=-tetramethylbenzidine (TMB)
substrate. The reaction was stopped by adding 25l H2SO4 (2N), and the
optical density at 450 nm was read in an ELISA microplate spectropho-
tometer (SpectraMax Plus; Molecular Devices, Canada).
Biopanning cycles: negative selection.To carry out negative selection
in the biopanning cycles, 1  1011 viral particles from a phage library
containing random seven peptides fused to a minor coat protein of M13
filamentous phages (Ph.D.-C7C library; New England BioLabs, USA)
were diluted in 190l of TBS-T buffer. The mixture was incubated for 30
min at room temperature with themicrospheres coupled to IgGs that had
been purified from healthy dogs, and then it was precipitated bymagnetic
attraction to produce a Dynal Biotech support. The supernatant contain-
ing the clones that were not adhered to the IgGs was recovered and trans-
ferred to a new tube, and this procedure using IgGs fromhealthy dogs was
repeated three times. After this, the supernatant was recovered and trans-
ferred to a new tube containing microspheres coupled to IgGs from T.
cruzi-infected dogs, and this procedure of negative selection was also re-
peated three times; the supernatant containing the phage clones that did
not adhere to the IgGs fromT. cruzi-infected dogs was recovered, titrated,
and used in the positive selection.
Positive selection. For positive selection, the previously recovered
phage clones were transferred to a tube containing microspheres coupled
to IgGs purified from serum samples of dogs with asymptomatic VL and
incubated for 30 min at room temperature. After, the supernatant was
removed and the remaining phages that were bound to the IgGs were
washed 10 times with 1 ml of TBS-T and eluted in 500 l of 0.2 M glycine
buffer (pH 2.0). Next, 75 l of 1 M Tris-base (pH 9.0) was added to
neutralize the acidic pH. Subsequently, the recovered phage clones were
transferred to a new tube containing IgGs that had been purified from
serum samples of dogs with symptomatic VL. The process was repeated
three times with serum samples of dogs with asymptomatic and symp-
tomatic VL, and the selected phage clones were recovered and titrated.
Titration of selected phage clones. Phage clones were diluted 101 to
1011 in 500l of sterile phosphate-buffered saline (PBS), mixed with an
Escherichia coli culture (optical density at 600 nm [OD600], 0.5), and
plated on LB agar plates containing 1 ml of isopropyl-	-D-thiogalactopy-
ranoside (IPTG)–X-Gal (1.25 g IPTG, 1 g 5-bromo-4-chloro-3-indolyl-
	-D-galactoside, and 25 ml of dimethyl sulfoxide [DMSO]). The colonies
were individually quantified, and the titration was performed for each
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biopanning cycle. After the 3rd cycle of positive selection, 96 colonieswere
selected from the plate and added to 200 l of LB in a sterile culture plate
(BD Falcon clear 96-well Microtest plate), and then the plate was sealed
and incubated for 5 h with constant stirring at 37°C. After incubation, the
plate was centrifuged for 20 min at 2,250  g and the supernatant was
transferred to a new plate, in which a polyethylene glycol (PEG)-NaCl
(20% PEG 8000 and 2.5 M NaCl) solution was added (1/6 of the total
volume of the supernatant), and the plate was incubated for 16 h at 4°C.
Afterward, the platewas centrifuged for 1 h, the supernatantwas removed,
and the pellet was resuspended in 500l of a solution composed of 10mM
Tris-HCl (pH 8.0), 1 mM EDTA, and 4 M NaI. The plate was shaken
vigorously for 5 min, and 250 l of a 70% ethanol solution was added.
After incubation for 10 min, the plate was centrifuged (2,250  g at 4°C
for 10 min) and the supernatant was discarded. The pellet containing the
DNA of interest of each phage clone was washed with 500 l of 70%
ethanol and centrifuged again. Finally, the DNA was diluted in 20 l of
ultrapure water and its quality was evaluated in a 1% agarose gel, which
was stained with an ethidium bromide solution (10 g/ml). The DNA
from individual clones was used for the sequencing and identification of
target peptides.
DNA sequencing and bioinformatics. The sequencing reaction was
performed with 500 ng of DNA for each selected phage clone, 5 pmol
primer 96 gIII (5=-OH CC TCA TAG TTA GCG TAA CG-3=; New Eng-
land BioLabs), plus a premix (Dye Terminator cycle ET journal kit; Am-
ersham Biosciences). Thirty-five cycles were performed in a thermocycler
under the following conditions: denaturation at 95°C for 20 s, ringing at
58°C for 15 s, and extension at 60°C for 60 s. The generated amplicons
were precipitated with 1 l of ammonium acetate and 27.5 l of ethanol.
The plate was centrifuged for 45 min at 2,432  g, the supernatant was
discarded, and 150 l of 70% ethanol was added to the pellet. The resus-
pendedDNAwas centrifuged for 10min at 2,432 g, and the supernatant
was discarded. The plate was inverted on a paper towel and was centri-
fuged in that position at 486 g for 1min. Next, the plate was covered for
5 min until complete evaporation of the remaining ethanol had been
achieved. The pellet was resuspended in dilution buffer, and sequencing
was performed in a MegaBACE 1000 automatic sequencer (Amersham
Biosciences). The peptide sequences were deduced using the ExPASy
server (see www.expasy.org), and they were analyzed by BLAST (see http:
//blast.ncbi.nlm.nih.gov/Blast.cgi) against the protein and motifs of the
GenBank database. Further analyses of multiple sequence alignments
were performed using the Clustal W2 program (see www.ebi.ac.uk). In
addition, calculations of the frequency of each amino acid and the amino
acid diversity within the population of peptides in the selected phage
clones were performed using the AADIV program (see http://www
.northeastern.edu/xray/downloads/aadiv-program/). The frequencies of
the amino acid residues of the original library were obtained according to
the manufacturer’s instructions (E8102L, Ph.D.-C7C library; New Eng-
land BioLabs, USA).
Phage-ELISA. Previous titration curves were performed to determine
the most appropriate phage concentration and antibody dilution to be
used. Falcon flexible microtiter plates (Becton, Dickinson) were coated,
each containing 18 individual clones (1 109 phages per well) diluted in
FIG 1 Schedule of the technical protocol used in subtractive selection by phage display technology.
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a 100-l coating buffer (50mMcarbonate buffer) (pH9.6) for 16 h at 4°C.
A random nonspecific phage clone (NMSDFLRIQLRS) was used as a
control. After sensitization, free binding sites were blocked using 200l of
a blocking solution (consisting of TBS, 0.05% Tween 20, and 5% nonfat
dry milk solution) for 1 h at 37°C. After plates were washed 5 times with
TBS-T, they were incubated with 100l of individual canine blood serum
(diluted 1:100) for 1 h at 37°C. The plates were washed 7 times using
TBS-T and incubatedwith a 1:8,000 anti-dog IgGhorseradish peroxidase-
conjugated antibody (Sigma, St. Louis, MO, USA) for 1 h at 37°C. After
the plates were washed 7 times with TBS-T, the reaction was developed
through incubation with H2O2, o-phenylenediamine, and citrate-phos-
phate buffer (pH 5.0) for 30min in the dark. The reaction was stopped by
adding 25 l H2SO4 (2 N), and the optical density at 492 nm was read in
an ELISA microplate spectrophotometer.
Data analysis. Statistical analyses were performed using GraphPad
Prism (version 5.0 for Windows), Win Episcope (version 2.0 for Win-
dows), andMicrosoft Excel (version 10.0). Twodifferent approacheswere
used to measure the reactivity of each serum sample for each selected
phage clone. First, the mean optical density (OD) value was calculated by
subtracting the mean blank OD frommean OD for each sample by using
specific values for the phage-ELISA. In a second approach, the normalized
absorbance ratio (NAR) was computed by further correcting the mean
OD value for each sample from each phage-ELISA by dividing it by the
equivalent mean result from the wild-type phage. As a consequence, the
NARs representmultiples of reactivitywith respect to that of thewild-type
phage (29). In addition, for each plate, outliers were evaluated using
Grubb’s test (30) and excluded from statistical analyses. The cutoff values
for each phage were determined by using a receiver operating character-
istic (ROC) analysis and by obtaining 100% specificity. The ROC curves
were plotted with the values from serum samples from dogs with symp-
tomatic VL versus those from the control groups (T. cruzi-infected, E.
canis-infected, Leishmune- or Leish-Tec-immunized, and healthy dogs),
according to a sick/nonsick rating method, where the criteria of inclusion
in each group was the positivity or negativity of PCR-RFLP in the blood
samples (31). Tables of contingency and Fisher’s exact test (P 0.05)were
used to compare the diagnostic performances. This was estimated by as-
sessing sensitivity (95% confidence interval [CI]), specificity (95% CI),
positive predictive value (PPV), negative predictive value (NPV), and di-
agnostic odds ratios (DORs). The accuracy was evaluated according to the
area under the curve (AUC) relative to theROCcurve (95%CI) andby the
Youden index (J) (95% CI) (32). Agreement beyond chance was assessed
using the kappa (
) coefficient (95% CI) (33) and interpreted according
to the following scale: 0.00 to 0.20 (negligible), 0.21 to 0.40 (weak), 0.41 to
0.60 (moderate), 0.61 to 0.80 (good), and 0.81 to 1.00 (excellent) (34). The
Kruskal-Wallis test, followed by the Dunn posttest for multiple compar-
isons, was used to compare differences between the CVL and control
groups (P 0.05).
RESULTS
Affinity selection of phage clones selected byCVL sera.Negative
selection was performed by excluding phage clones that were rec-
ognized by antibodies present in serum samples from healthy and
T. cruzi-infected dogs. Afterward, the positive selection process
was performed by recovering the phage clones from the previous
step, and those that were recognized by antibodies present in the
serum samples from dogs with asymptomatic and symptomatic
CVL were selected. The technical protocol representing each of
three biopanning cycles is summarized in Fig. 1. Approximately
96 clones were randomly selected from individual colonies, and
their DNA sequences were PCR amplified and sequenced. Eigh-
teen clones had their sequences clearly identified (Table 1), and an
alignment showed that no identical consensus motif could be de-
tected between them (data not shown). Table 2 shows a compar-
ison between the expected and found frequencies of 20 amino
acids in the ligand peptides present in the selected phage clones
obtained from the original library.
Assessment of the diagnostic performance of selected phage
clones. To investigate the diagnostic performance of 18 selected
phage clones, the individual phages were analyzed by phage-
ELISA regarding their reactivities using a diverse serological panel
(Table 3). From the 18 selected phage clones, nine (A1, A8, C7, C9,
E7, E8, F12, G8, and H7) clones presented a perfect agreement
beyond chance, with kappa values ranging from 0.917 to 1.0. The
cutoff values were chosen to obtain 100% specificity. Considering
TABLE 1 Amino acid sequences from target peptides present in the
selected phage clones
Clone Amino acid sequence
A1 TSPPLHA
A8 DPRAADP
A9 QSTSGSS
C7 NPFLADP
C9 SPDSLFP
D9 PQDPKQW
E5 LYHDTHY
E7 NPFCGSR
E8 PRSSLPS
F1 TFSPLSV
F10 VHSPFWP
F12 PSPSRFP
G7 PRSTSHL
G8 FGAPVSL
H1 FPHLSRY
H5 SPWPLSY
H7 YPGMLWT
H9 IWSPFFD
RPa NMSDFLRIQLRS
a RP, random phage.
TABLE 2 Analysis of the expected and present amino acid frequencies
in the peptides expressed on selected phage clones display after selection
procedures
Amino acid
Frequency (%)
Expected Present
Alanine 6.20 3.97
Cysteine 3.10 0.79
Aspartic acid 3.10 5.56
Glutamic acid 3.10 0.00
Phenylalanine 3.10 7.94
Glycine 6.20 3.17
Histidine 3.10 4.76
Isoleucine 3.10 0.79
Lysine 3.10 0.79
Leucine 9.40 8.73
Methionine 3.10 0.79
Asparagine 3.10 1.59
Proline 6.20 20.63
Glutamine 6.20 2.38
Arginine 9.40 4.76
Serine 9.40 18.25
Threonine 6.20 4.76
Valine 6.20 2.38
Tryptophan 3.10 3.97
Tyrosine 3.10 3.97
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this requirement, eight clones (A1, A8, C7, C9, E7, E8, F12, and
G8) accurately differentiated L. infantum-infected dogs from the
control groups, thus avoiding false-negative results. Additionally,
these selected phage clones showed highly accurate ROC curves
(AUC, 1.0) and statistically significant values (P 0.0001) when
analyzed by Fisher’s exact test (Table 3). The measures of individ-
ual performance for each evaluated phage are shown in Table 4.
The higher sensitivity (100%) and Youden index (1.00) were ob-
tained by eight selected phage clones. These clones showed speci-
ficities and PPVs of 100% and NPVs ranging from 90% to 100%.
The highestDORswere achieved byA8,C7, E7, andE8, presenting
a value of 4,125, while the A1 and F12 clones achieved a DOR of
4,059 and the G8 clone achieved a DOR of 3,993. Figure 2 shows
the results from the NAR of the serum samples, and Fig. 3 shows
the ROC curves in relation to the selected phage clones that pre-
sented the best results. Additionally, all phage clones differenti-
ated L. infantum-infected dogs from the control groups, with sta-
tistical significance evaluated by the Kruskal-Wallis test followed
by the Dunn posttest (P 0.0001).
To characterize phage ligands, specificity is defined as the abil-
ity of a phage probe to associate with its target due to the presence
of a specific peptide sequence displayed on the surface of the
phage, whereas selectivity is the ability of a phage probe to identify
its cognate target from a mixture of targets (35). In this context, a
random phage selected by biopanning cycles using serum samples
from dogs without CVLwas used as a control in the phage-ELISA,
in order to demonstrate that the specificity and selectivity of the
selected clones were in fact due to the exogenous peptide of inter-
est and not to any other endogenous phage component. As shown
in Tables 3 and 4, this random phage clone failed to differentiate
between the sera fromL. infantum-infected dogs and that from the
control groups, and it provided poor diagnostic performance for
CVL.
DISCUSSION
The present study describes a subtractive phage display strategy
that led to the identification of novel antigens to aid in CVL sero-
diagnosis. The selected phage clones were able to discriminate the
serum samples from L. infantum-infected dogs from the cross-
reactive serum samples infected by other parasites, as well as from
the serum samples from vaccinated dogs using a phage-ELISA
technique. Since its first description (36) and introduction into
laboratory practice (37), phage display technology has proven to
be useful in selecting specific peptides that are highly reactive
against many pathogen targets. Its biological applications have
ranged from use in studies of vaccine candidates for rabies (38),
hepatitis C (39), E. coli (40), Plasmodium vivax (23), and Schisto-
soma japonicum (41) to use with diagnostic antigens for the detec-
tion of antibodies to pneumonia (42), neurocysticercosis (43–45),
equine viral arteritis (46), rabies (47), and anaplasmosis (48).
These phage-displayed peptides, also called mimotopes, have
shown either linear or conformational recognition with high af-
finity to paratope sequences of antibodies. In this context, the
present study used a subtractive approach through phage display
in order to identify new antigens for the serodiagnosis of CVL so as
to identify phage clones that express target peptides capable of
being recognized by antibodies present in the serum samples from
L. infantum-infected dogs. Aimed at identifying more refined an-
tigens forCVL serodiagnosis, the selected phage cloneswere tested
in a serological panel in phage-ELISAs.
TABLE 3 Diagnostic performance of clones by phage-ELISA using ROC curves, data validation, and agreement to identify L. infantum-infected
dogs
Clone AUCb 95% CIc
No. of serum
samples used
No. of samples with indicated
resultd
Pe 
 95% CITP TN FP FN
A1 1.000 1.000–1.000 77 16 61 0 0 0.0001 1.000 1.000–1.000
A8 1.000 1.000–1.000 78 16 62 0 0 0.0001 1.000 1.000–1.000
A9 0.989 0.974–1.000 78 10 62 6 0 0.0001 0.726 0.521- 0.931
C7 1.000 1.000–1.000 78 16 62 0 0 0.0001 1.000 1.000–1.000
C9 0.873 0.711–1.000 74 13 60 1 0 0.0001 0.955 0.867–1.000
D9 0.993 0.981–1.000 76 11 62 3 0 0.0001 0.857 0.699.1.000
E5 0.998 0.992–1.000 76 13 61 2 0 0.0001 0.913 0.793–1.000
E7 1.000 1.000–1.000 78 16 62 0 0 0.0001 1.000 1.000–1.000
E8 1.000 1.000–1.000 78 16 62 0 0 0.0001 1.000 1.000–1.000
F1 0.989 0.974–1.000 78 11 62 5 0 0.0001 0.778 0.593- 0.963
F10 0.949 0.889–1.000 77 12 61 4 0 0.0001 0.826 0.662- 0.990
F12 1.000 1.000–1.000 77 16 61 0 0 0.0001 1.000 1.000–1.000
G7 0.949 1.000–1.000 77 6 61 10 0 0.0001 0.487 0.207–0.768
G8 1.000 1.000–1.000 76 16 60 0 0 0.0001 1.000 1.000–1.000
H1 0.571 1.000–1.000 78 2 62 14 0 0.0400 0.185 0.185 to 0.555
H5 0.962 0.922–1.000 78 8 62 8 0 0.0001 0.614 0.371–0.857
H7 0.998 0.923–1.000 77 14 61 2 0 0.0001 0.917 0.805–1.000
H9 0.795 0.964–0.897 78 1 62 15 0 NS 0.096 0.307 to 0.499
RPa 0.579 0.419–0.739 78 0 62 16 0 NS
a RP, random phage.
b AUC, area under the curve.
c CI, confidence interval.
d TP, true positive; TN, true negative; FP, false positive; FN, false negative.
e Statistical significance determined by Fisher’s exact test. NS, no significance.
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Serological tests are currently recommended for the laborato-
rial diagnosis of CVL. IFAT and ELISA are the most widely used
diagnostic assays that are applicable to leishmaniasis; however,
their low sensitivities for detecting cases with low levels of Leish-
mania-specific antibodies, as well as their cross-reactivity with
other diseases, includingChagas’ disease represent important lim-
itations for their use in the CVL serodiagnosis (49, 50). In addi-
tion, crude antigens are also limited by the difficulty in producing
large quantities in a standardized manner. Moreover, a high per-
centage of dogs, though infected by Leishmania, can remain sero-
negative for various periods of time, which can present as false-
negative results in the serological trials (7, 51, 52).
In evaluating the amino acid residues present in the peptide
sequence exposed in the selected phage clones, it is possible to
conclude that the negative and positive selection processes we em-
ployed in the phage display strategy are effective once cysteine,
lysine, and glycine amino acids were selected as presenting a fre-
quency lower than the one expected, while the proline amino acid
presented a frequency three times higher than expected, suggest-
ing that this amino acid might be involved in antigen-antibody
interactions. In fact, it is known that proline limits the flexibility of
peptides andmay therefore favor the formation of themonoclonal
antibody (MAb)-peptide complex (53). In addition, this amino
acid presents a chemically cohesive and rigid structure, resulting
in a cyclic format that strongly influences the architecture of pro-
teins (54, 55). Thus, the presence of proline in the majority of the
selected peptides might suggest that this amino acid confers a
more stable spatial conformation that interacts better with the IgG
antibodies used in the positive and negative selection processes.
Regarding the sensitivity and specificity found in this study for
selected phage clones, the high performance observed for phage-
ELISA using the A1, A8, C7, E7, E8, F12, and G8 clones is com-
patiblewith the diagnostic performance observed in recent studies
using recombinant proteins (56, 57), multiple-epitope chimeric
antigens (58, 59), and synthetic peptides (60, 61). Nevertheless,
the results of this study show improvements in sensitivity (100%)
and specificity (100%), given that the cutoff values were selected
in an attempt to obtain 100% specificity. Moreover, no false-pos-
itive result was observed when ROC curves were plotted, despite
regular cross-reactive conditions, such as dogs that were infected
with T. cruzi or E. canis and animals immunized with Leishmune
or Leish-Tec Brazilian commercial vaccine. Recently, Faria et al.
(62) performed an ELISA using a mixture of synthetic antigens
and obtained high sensitivity and specificity values (78.5% and
80%, respectively); however, all of the synthetic antigens and the
mixture presented high cross-reactivity with serum samples from
T. cruzi-infected dogs. In addition, Marcondes et al. (63), who
performed a rapid ELISA, showed a high rate of false-positive
results in which high percentages of cross-reactivity occurred be-
tween Leishmania spp. and T. cruzi (57%), as well as between
Leishmania spp. and E. canis (57%).
In this study, the PPV,NPV, andDORparameters were used to
compare the performances of the selected clones in the phage-
ELISAs, indicating those that were true positives or true negatives
to infection. All phage clones showed high PPV (100%); therefore,
a positive result using any one of these indicates almost certain
ocurrence of infection. Regarding the NPV, only the G7, H5, and
H9 clones obtained lower values, ranging from 80.5% to 88.6%.
The highest DORs were achieved by the A8, C7, E7, and E8 phage
clones, which reached a value of 4,125. This parameter is themea-
sure of the ratio between the DOR of the positivity found in those
with the disease and the DOR of the positivity found in those with
TABLE 4 Diagnostic performance of the phage-ELISA using different blood serum samples
Clone
Sensitivity Specificity
Jc PPVd NPVe DORf% 95% CIb % 95% CI
A1 100.00 79.41–100.00 100.00 94.13–100.00 1.000 100.00 100.00 4,059
A8 100.00 79.41–100.00 100.00 94.13–100.00 1.000 100.00 100.00 4,125
A9 62.50 35.43–84.80 100.00 94.22–100.00 0.625 100.00 91.18 202
C7 100.00 79.41–100.00 100.00 94.13–100.00 1.000 100.00 100.00 4,125
C9 92.86 66.13–99.82 100.00 94.13–100.00 0.929 100.00 98.36 1,089
D9 78.57 49.20–95.34 100.00 94.22–100.00 0.786 100.00 95.38 411
E5 86.67 59.54–98.34 100.00 94.13–100.00 0.867 100.00 96.83 664
E7 100.00 79.41–100.00 100.00 94.13–100.00 1.000 100.00 100.00 4,125
E8 100.00 79.41–100.00 100.00 94.13–100.00 1.000 100.00 100.00 4125
F1 68.75 41.34- 88.98 100.00 94.22–100.00 0.687 100.00 92.54 261
F10 75.00 47.62–92.73 100.00 94.13–100.00 0.750 100.00 93.85 342
F12 100.00 79.41–100.00 100.00 94.13–100.00 1.000 100.00 100.00 4059
G7 37.50 15.20- 64.57 100.00 94.13–100.00 0.375 100.00 85.92 76
G8 100.00 79.41–100.00 100.00 94.13–100.00 1.000 100.00 100.00 3993
H1 12.50 01.55–38.35 100.00 94.22–100.00 0.012 100.00 100.00 21
H5 50.00 24.65–75.35 100.00 94.22–100.00 0.500 100.00 88.57 125
H7 87.50 61.65–98.45 100.00 94.13–100.00 0.875 100.00 96.83 713
H9 6.25 00.16–30.23 100.00 94.22–100.00 0.062 100.00 80.52 12
RPa 0 0.00–00.20 100.00 91.34–99.96 0 100.00 79.22 1
a RP, random phage.
b CI, confidence interval.
c J, Youden index.
d PPV, positive predictive value.
e NPV, negative predictive value.
f DOR, diagnostic odds ratio.
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FIG 2 Phage-ELISA reactivity using the selected phage clones against different blood serum samples. Shown are box plots with minimum andmaximum values
of normalized absorbance ratios (NARs) between dogs with CVL (n 16) and healthy (n 17) or vaccinated (n 21) dogs or dogs with cross-reacting diseases
(T. cruzi and E. canis; n 23)., outliers; ***, P values of0.0001 represent statistically significant differences between CVL and control groups, as determined
by the Kruskal-Wallis test, followed by Dunn’s posttest for multiple comparisons.
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FIG 3 Diagnostic performance (sensitivity and specificity) of selected phage clones using different serum samples. ROC curves were plotted with the values of
dogs with VL versus control groups (healthy, immunized with Leishmune or Leish-Tec, T. cruzi-infected, or E. canis-infected dogs). The ROC curves were
calculated to determine the ELISA cutoff values and the AUC.
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no disease (64). Recently, Rodríguez-Cortés et al. (65) compared
six commercially available tests for the serodiagnosis of CVL and
observed that the results presented a PPV of 100%, while the NPV
ranged from 50% to 93%. In the same study, the DOR ranged
from 47 to 729.
The serological panel employed in the present study did not
contain samples from L. braziliensis-infected dogs; the collection
of the serum samples from dogs was restricted to the urban area of
Belo Horizonte, where the low incidence of infection with L. bra-
ziliensis in dogs was recently described (66). Thus, the data from
this study should be taken as a proof-of-concept of the capacity of
the proposed synthetic antigens to aid in the serodiagnosis ofCVL,
and theymay well serve as a reference for further assays. However,
these novel highly accurate phage-fused peptides and their use in
phage-ELISAs may be promptly applied in the serodiagnosis used
in CVL-monitoring programs due to their simplicity, ease of use,
reproducibility, and low cost.
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